» Articles » PMID: 21454522

Discovery of a Novel Site Regulating Glucokinase Activity Following Characterization of a New Mutation Causing Hyperinsulinemic Hypoglycemia in Humans

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2011 Apr 2
PMID 21454522
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes is a global problem, and current ineffective therapeutic strategies pave the way for novel treatments like small molecular activators targeting glucokinase (GCK). GCK activity is fundamental to beta cell and hepatocyte glucose metabolism, and heterozygous activating and inactivating GCK mutations cause hyperinsulinemic hypoglycemia (HH) and maturity onset diabetes of the young (MODY) respectively. Over 600 naturally occurring inactivating mutations have been reported, whereas only 13 activating mutations are documented to date. We report two novel GCK HH mutations (V389L and T103S) at residues where MODY mutations also occur (V389D and T103I). Using recombinant proteins with in vitro assays, we demonstrated that both HH mutants had a greater relative activity index than wild type (6.0 for V389L, 8.4 for T103S, and 1.0 for wild type). This was driven by an increased affinity for glucose (S(0.5), 3.3 ± 0.1 and 3.5 ± 0.1 mm, respectively) versus wild type (7.5 ± 0.1 mm). Correspondingly, the V389D and T103I MODY mutants had markedly reduced relative activity indexes (<0.1). T103I had an altered affinity for glucose (S(0.5), 24.9 ± 0.6 mm), whereas V389D also exhibited a reduced affinity for ATP and decreased catalysis rate (S(0.5), 78.6 ± 4.5 mm; ATP(K(m)), 1.5 ± 0.1 mm; K(cat), 10.3 ± 1.1s(-1)) compared with wild type (ATP(K(m)), 0.4 ± <0.1; K(cat), 62.9 ± 1.2). Both Thr-103 mutants showed reduced inhibition by the endogenous hepatic inhibitor glucokinase regulatory protein. Molecular modeling demonstrated that Thr-103 maps to the allosteric activator site, whereas Val-389 is located remotely to this position and all other previously reported activating mutations, highlighting α-helix 11 as a novel region regulating GCK activity. Our data suggest that pharmacological manipulation of GCK activity at locations distal from the allosteric activator site is possible.

Citing Articles

Mild Congenital Hyperinsulinism Caused by Mutation in Human Gene.

Sozaeva L, Ismailova S, Chernyak I, Popov S, Zakharova V, Chugunov I JCEM Case Rep. 2024; 2(12):luae226.

PMID: 39659388 PMC: 11630036. DOI: 10.1210/jcemcr/luae226.


Genotype-histotype-phenotype correlations in hyperinsulinemic hypoglycemia.

Larsen A, Brusgaard K, Christesen H, Detlefsen S Histol Histopathol. 2024; 39(7):817-844.

PMID: 38305063 DOI: 10.14670/HH-18-709.


TWO OPPOSITE PHENOTYPES OF GLUCOSE DISORDERS IN A FAMILY WITH HETEROZYGOUS P.SER453LEU (C.1358C> T) MUTATION IN THE GLUCOKINASE (GCK) GENE: MATURITY ONSET DIABETES IN YOUNG AND INSULINOMA.

Demiral M, Celebi H, Cander S, Yerci O, Eren E, Demirbilek H Acta Endocrinol (Buchar). 2023; 18(4):458-465.

PMID: 37152879 PMC: 10162830. DOI: 10.4183/aeb.2022.458.


The insulin centennial-100 years of milestones in biochemistry.

Attie A, Tang Q, Bornfeldt K J Biol Chem. 2021; 297(5):101278.

PMID: 34717954 PMC: 8605089. DOI: 10.1016/j.jbc.2021.101278.


The insulin centennial-100 years of milestones in biochemistry.

Attie A, Tang Q, Bornfeldt K J Lipid Res. 2021; 62:100132.

PMID: 34717951 PMC: 8721491. DOI: 10.1016/j.jlr.2021.100132.


References
1.
Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y . Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure. 2004; 12(3):429-38. DOI: 10.1016/j.str.2004.02.005. View

2.
Burke C, Buettger C, Davis E, McClane S, Matschinsky F, Raper S . Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinaemia (GK-HI). Biochem J. 1999; 342 ( Pt 2):345-52. PMC: 1220471. View

3.
Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson A . New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010; 42(2):105-16. PMC: 3018764. DOI: 10.1038/ng.520. View

4.
Matschinsky F, Porte D . Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Med Rep. 2010; 2. PMC: 2950051. DOI: 10.3410/M2-43. View

5.
Weedon M, Clark V, Qian Y, Ben-Shlomo Y, Timpson N, Ebrahim S . A common haplotype of the glucokinase gene alters fasting glucose and birth weight: association in six studies and population-genetics analyses. Am J Hum Genet. 2006; 79(6):991-1001. PMC: 1698701. DOI: 10.1086/509517. View